Yousif Capital Management LLC Sells 554 Shares of Vericel Corporation (NASDAQ:VCEL)

Yousif Capital Management LLC reduced its holdings in Vericel Corporation (NASDAQ:VCEL) by 2.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 18,512 shares of the biotechnology company’s stock after selling 554 shares during the quarter. Yousif Capital Management LLC’s holdings in Vericel were worth $826,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the business. Meeder Asset Management Inc. increased its stake in Vericel by 8.4% during the 4th quarter. Meeder Asset Management Inc. now owns 2,357 shares of the biotechnology company’s stock worth $129,000 after purchasing an additional 183 shares in the last quarter. Atria Investments Inc boosted its holdings in shares of Vericel by 2.4% in the fourth quarter. Atria Investments Inc now owns 7,952 shares of the biotechnology company’s stock valued at $437,000 after buying an additional 184 shares during the period. Captrust Financial Advisors increased its position in shares of Vericel by 3.4% during the fourth quarter. Captrust Financial Advisors now owns 6,111 shares of the biotechnology company’s stock worth $336,000 after acquiring an additional 199 shares in the last quarter. Avantax Advisory Services Inc. increased its position in shares of Vericel by 1.7% during the fourth quarter. Avantax Advisory Services Inc. now owns 13,803 shares of the biotechnology company’s stock worth $758,000 after acquiring an additional 234 shares in the last quarter. Finally, Summit Investment Advisors Inc. raised its holdings in shares of Vericel by 8.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 5,137 shares of the biotechnology company’s stock worth $282,000 after acquiring an additional 405 shares during the period.

Vericel Stock Performance

NASDAQ:VCEL opened at $41.78 on Friday. The company has a market cap of $2.10 billion, a price-to-earnings ratio of 1,393.13 and a beta of 1.33. Vericel Corporation has a fifty-two week low of $37.39 and a fifty-two week high of $63.00. The stock has a fifty day moving average price of $41.43 and a 200-day moving average price of $49.27.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.14). Vericel had a net margin of 1.25% and a return on equity of 1.09%. The company had revenue of $52.60 million during the quarter, compared to analyst estimates of $53.86 million. During the same period last year, the firm earned ($0.08) EPS. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. Research analysts predict that Vericel Corporation will post 0.14 EPS for the current fiscal year.

Insider Activity

In related news, CEO Dominick Colangelo sold 24,850 shares of the stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $41.89, for a total transaction of $1,040,966.50. Following the sale, the chief executive officer now owns 260,354 shares in the company, valued at approximately $10,906,229.06. This trade represents a 8.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 5.20% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on VCEL shares. Stephens reiterated an “overweight” rating and set a $67.00 target price on shares of Vericel in a report on Monday. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of Vericel in a report on Friday, February 28th. Wall Street Zen lowered Vericel from a “hold” rating to a “sell” rating in a research report on Monday, May 12th. Finally, Truist Financial cut their target price on Vericel from $61.00 to $51.00 and set a “buy” rating on the stock in a research note on Friday, April 11th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $61.14.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.